Mihaela Aldea

Mihaela Aldea

Auto-generated profile, based on publicly available information

Mihaela Aldea

Medical Oncology Department, Institut Gustave Roussy, Villejuif, France

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
MAMihaela Aldea
Mihaela Aldea
FAFabrice Andre
Fabrice Andre
AMAurelien Marabelle
Aurelien Marabelle
SDSemih Dogan
Semih Dogan
FBFabrice Barlesi
Fabrice Barlesi
JSJean-Charles Soria
Jean-Charles Soria
Resistance to anticancer therapies includes primary resistance, usually related to lack of target dependency or presence of additional targets, and secondary resistance, mostly driven by adaptation of the cancer cell to the selection pressure of treatment. Resistance to targeted therapy is frequently acquired, driven by on-target, bypass alterations, or cellular plasticity. Resistance to immunotherapy is often primary, orchestrated by sophisticated tumor–host–microenvironment interactions, but could also occur after initial efficacy, mostly when only partial responses are obtained. Here, we provide an overview of resistance to tumor and immune-targeted therapies and discuss challenges of overcoming resistance, and current and future directions of development.Significance: A better and earlier identification of cancer-resistance mechanisms could avoid the use of ineffective drugs in patients not responding to therapy and provide the rationale for the administration of personalized drug associations. A clear description of the molecular interplayers is a prerequisite to the development of novel and dedicated anticancer drugs. Finally, the implementation of such cancer molecular and immunologic explorations in prospective clinical trials could de-risk the demonstration of more effective anticancer strategies in randomized registration trials, and bring us closer to the promise of cure.

17 April 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
MNMarcelo V. Negrao
Marcelo V. Negrao
HAHaniel A. Araujo
Haniel A. Araujo
GLGiuseppe Lamberti
Giuseppe Lamberti
ACAlissa J. Cooper
Alissa J. Cooper
NANeal S. Akhave
Neal S. Akhave
FSFerdinandos Skoulidis
Ferdinandos Skoulidis
Molecular modifiers of KRASG12C inhibitor (KRASG12Ci) efficacy in advanced KRASG12C-mutant NSCLC are poorly defined. In a large unbiased clinicogenomic analysis of 424 patients with non–small cell lung cancer (NSCLC), we identified and validated coalterations in KEAP1, SMARCA4, and CDKN2A as major independent determinants of inferior clinical outcomes with KRASG12Ci monotherapy. Collectively, comutations in these three tumor suppressor genes segregated patients into distinct prognostic subgroups and captured ∼50% of those with early disease progression (progression-free survival ≤3 months) with KRASG12Ci. Pathway-level integration of less prevalent coalterations in functionally related genes nominated PI3K/AKT/MTOR pathway and additional baseline RAS gene alterations, including amplifications, as candidate drivers of inferior outcomes with KRASG12Ci, and revealed a possible association between defective DNA damage response/repair and improved KRASG12Ci efficacy. Our findings propose a framework for patient stratification and clinical outcome prediction in KRASG12C-mutant NSCLC that can inform rational selection and appropriate tailoring of emerging combination therapies. Significance: In this work, we identify co-occurring genomic alterations in KEAP1, SMARCA4, and CDKN2A as independent determinants of poor clinical outcomes with KRASG12Ci monotherapy in advanced NSCLC, and we propose a framework for patient stratification and treatment personalization based on the comutational status of individual tumors. See related commentary by Heng et al., p. 1513. This article is highlighted in the In This Issue feature, p. 1501

1 December 2020 in European Journal of Cancer
Verified
Journal Article
Closed access
MAMihaela Aldea
Mihaela Aldea
EOEmeline Orillard
Emeline Orillard
LMLaura Mansi
Laura Mansi
AMAurélien Marabelle
Aurélien Marabelle
FSFlorian Scotte
Florian Scotte
Jean Marie MichotJean Marie Michot
Jean Marie Michot

14 January 2025 in Trends in Cancer
Verified
Journal Article
Open access
MLMarta Ligero
Marta Ligero
ONOmar S.M. El Nahhas
Omar S.M. El Nahhas
MAMihaela Aldea
Mihaela Aldea
JKJakob Nikolas Kather
Jakob Nikolas Kather
The development of new therapeutic strategies such as immune checkpoint inhibitors (ICIs) and targeted therapies has increased the complexity of the treatment landscape for solid tumors. At the current rate of annual FDA approvals, the potential treatment options could increase by tenfold over the next 5 years. The cost of personalized medicine technologies limits its accessibility, thus increasing socioeconomic disparities in the treated population. In this review we describe artificial intelligence (AI)-based solutions - including deep learning (DL) methods for routine medical imaging and large language models (LLMs) for electronic health records (EHRs) - to support cancer treatment decisions with cost-effective biomarkers. We address the current limitations of these technologies and propose the next steps towards their adoption in routine clinical practice.

1 March 2020 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
MAMihaela Aldea
Mihaela Aldea
LHLizza Hendriks
Lizza Hendriks
LMLaura Mezquita
Laura Mezquita
CJCécile Jovelet
Cécile Jovelet
DPDavid Planchard
David Planchard
BBBenjamin Besse
Benjamin Besse

18 November 2025 in Annals of Oncology
Verified
Journal Article
Open access
MAM. Aldea
M. Aldea
MSM. Salto-Tellez
M. Salto-Tellez
AMAntonio Marra
Antonio Marra
RUR. Umeton
R. Umeton
ASA. Stenzinger
A. Stenzinger
JKJakob Nikolas Kather
Jakob Nikolas Kather
Artificial intelligence (AI) is expected to introduce an increasing number of biomarkers in oncology. To bridge the gap between oncology and computer science, it is timely to define recommendations for AI-based biomarkers suitable for routine clinical use. Here, we propose the ESMO (European Society for Medical Oncology) Basic Requirements for AI-based Biomarkers In Oncology (EBAI). The EBAI framework was developed using a modified Delphi methodology, involving a multidisciplinary panel of 37 experts who participated in four structured consensus rounds. AI-based biomarkers were classified as 'class A' (AI quantification of established biomarkers), 'class B' (indirect measure of known biomarkers using AI-based alternative methods, to be deployed as pre-screening tests), and 'class C' (novel AI-derived biomarkers, with C1 for prognosis and C2 for prediction of treatment effect). The EBAI framework addresses AI biomarkers for clinical use. Ground truth, performance, and generalisability were considered essential; fairness was recommended. Minimal validation requirements indicate that class A requires concordance studies, class B analytical validation, class C1 high-quality retrospective real-world or clinical trial data, and class C2 additionally requires clinical validation in prospective clinical trials for the prediction of response to a new treatment. All biomarker studies should report multiple evaluation and calibration metrics, with a clearly defined primary objective. Generalisability should be demonstrated across all intended use settings, including variability in data acquisition, post-processing, and population characteristics. Biomarkers must not be applied to other cancer types or modalities without supporting evidence. EBAI defines criteria for AI-based biomarker adoption in routine use, providing a common language for physicians, AI developers, and researchers.